Inscription Capital’s Biogen BIIB Stock Holding History

Inscription Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-656	Closed	-$208K	–	143
2020 Q1	$208K	Buy	+656	New	+$199K	0.14%	118

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Inscription Capital's BIIB Position: Q2 2020 in Review

Inscription Capital sold out of Biogen (BIIB) in Q2 2020, closing a stake of 656 shares — an estimated $208K sold.

Inscription Capital first reported a position in BIIB in Q1 2020 and held it in 1 quarter. The position peaked at $208K in Q1 2020. 1,059 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

Inscription Capital reported no remaining Biogen position as of Q2 2020 after selling out during the quarter.
Inscription Capital sold 656 Biogen shares in Q2 2020, an estimated $208K.
Inscription Capital first reported a position in Biogen in Q1 2020 and held it in 1 quarter.
Inscription Capital's Biogen position peaked at $208K in Q1 2020.
1,059 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Inscription Capital's 13F filing for Q2 2020, filed 11 Aug 2020.